| Literature DB >> 35414734 |
Vera Bain1, Anna Carlota Mott Galvão de Arruda Barrientos1, Lisa Suzuki1, Luiz Antonio Nunes de Oliveira1, Nadia Litvinov1, Karina Rodrigues Peron1, Juliana Folloni Fernandes1, Heloisa Helena de Sousa Marques1.
Abstract
Objective: To describe the radiological findings in pediatric patients with hematological or oncological diseases who also have an invasive fungal infection (IFI). Materials andEntities:
Keywords: Adolescent; Child; Immunocompromised host; Mycoses/diagnostic imaging; Tomography; X-ray computed
Year: 2022 PMID: 35414734 PMCID: PMC8993174 DOI: 10.1590/0100-3984.2021.0055
Source DB: PubMed Journal: Radiol Bras ISSN: 0100-3984
Clinical and imaging characteristics of pediatric patients with CT findings considered typical or atypical of IFI in the 2008 EORTC guidelines(.
| Characteristic | Chest CT findings | ||
|---|---|---|---|
| Typical (n = 29) | Atypical (n =11) | P-value | |
| Sex, n (%) | 0.48 | ||
| Female | 13 (45) | 7 (64) | |
| Male | 16 (55) | 4 (36) | ND |
| Underlying condition, n (%) | |||
| Acute lymphoblastic leukemia | 9 (31) | 3 (27) | |
| Acute myeloid leukemia | 13 (45) | 4 (36) | |
| Refractory to treatment or relapsed | 11 (38) | 2 (18) | |
| Autologous bone marrow transplant | 2 (7) | 1 (9) | |
| Allogeneic bone marrow transplant | 1 (3) | 1 (9) | |
| Other | 7 (24) | 4 (36) | |
| Age (months), median | 123 | 77 | 0.03 |
| Age group, n (%) | ND | ||
| ≤ 6 years | 8 (2) | 6 (55) | |
| 7–12 years | 9 (31) | 5 (45) | |
| ≥ 13 years | 12 (41) | 0 | |
| Neutropenia, n (%) | 28 (97) | 9 (82) | 0.17 |
| Days with neutropenia before | |||
| diagnosis, median | 15 | 11 | 0.04 |
| Broad-spectrum antibiotics, n (%) | 29 (100) | 11 (100) | ND |
| Corticosteroid therapy, n (%) | 6 (21) | 5 (45) | 0.13 |
| Chemotherapy, n (%) | 28 (97) | 9 (82) | 0.07 |
| Invasive devices, n (%) | 23 (79) | 10 (91) | 0.65 |
| Mucositis, n (%) | 23 (79) | 6 (55) | 0.13 |
| Signs and symptoms, n (%) | |||
| Fever | 29 (100) | 10 (91) | 0.27 |
| Respiratory distress | 16 (55) | 6 (55) | 1 |
| Pleuritic pain | 1 (3) | 0 (0) | 1 |
| Hemodynamic instability | 6 (21) | 6 (55) | 0.03 |
| Skin lesions | 0 (0) | 1 (9) | 0.27 |
| Duration (days) of fever, median | 9.0 | 5.5 | 0.30 |
| Intensive care unit admission | 10 (34) | 8 (73) | 0.04 |
| Antifungal prophylaxis | 17 (59) | 6 (55) | ND |
| Fluconazole | 2 (7) | 1 (9) | |
| Itraconazole | 7 (24) | 0 | |
| Voriconazole | 3 (10) | 1 (9) | |
| Micafungin | 5 (17) | 4 (36) | |
| Antifungal treatment | ND | ||
| Duration (days), median | 21 days | 22 days | 0.60 |
| Agent, n (%) | |||
| Fluconazole | 1 (3) | 0 | |
| Voriconazole | 5 (17) | 0 | |
| Amphotericin B | 12 (41) | 9 (82) | |
| Amphotericin B + fluconazole | 0 | 1 (9) | |
| Amphotericin B + voriconazole | 11 (38) | 1 (9) | |
| Outcome | 0.59 | ||
| Cure | 14 (48) | 7 (64) | |
| Death from IFI | 3 (10) | 2 (18) | |
| Death from other causes | 9 (31) | 2 (18) | |
| Loss to follow-up | 3 (10) | 0 | |
| Chest CT findings[ | |||
| Halo sign | 27 (93) | 0 (0) | 0.00 |
| Consolidation | 12 (41) | 8 (72) | 0.15 |
| Cavity | 7 (24) | 0 | 0.15 |
| Nodules | 1 (3) | 2 (18) | 0.17 |
| Ground-glass opacity | 19 (65) | 10 (91) | 0.23 |
| Pleural effusion | 10 (34) | 5 (45) | 0.71 |
| Other | 24 (82) | 8 (72) | 0.66 |
Neuroblastoma (n = 4); osteosarcoma (n = 2); astrocytoma (n = 1); hemangioendothelioma (n = 1); sarcoma (n = 1); pineoblastoma (n = 1); and retinoblastoma (n = 1).
1 finding (n = 4); 2 findings (n = 5); or ≥ 3 findings (n = 31). ND, no data.
Figure 1Findings typical of IFI on chest CT scans: multiple nodules with the halo sign (A); and cavities (B). C: Nodule without the halo sign (typical finding according to new guideline).
Demographic and clinical characteristics of patients with proven or probable IFI.
| Patient | Sex | Age (years) | Underlying condition | IFI status | Fungal isolate | Site(s) of detection | Symptoms | CT findings |
|---|---|---|---|---|---|---|---|---|
| 1 | Male | 6 | Acute lymphoblastic leukemia | Proven | Lung (biopsy) | Fever and respiratory distress | Halo sign; ground-glass opacities; bronchial wall thickening | |
| 2 | Male | 14 | Acute myeloid leukemia refractory or relapsed | Proven | Lung (biopsy) | Fever | Halo sign | |
| 3 | Female | 6 | Acute myeloid leukemia | Proven | Lung (biopsy) | Fever, shock and respiratory distress | Halo sign; consolidation; pleural effusion; ground-glass opacities; mosaic attenuation pattern; bronchial wall thickening | |
| 4 | Female | 6 | Acute myeloid leukemia | Proven |
| Central venous catheter | Fever and shock | Nodule |
| 5 | Female | 1 | Acute lymphoblastic leukemia | Proven | Lung (biopsy) | Fever and respiratory distress | Halo sign | |
| 6 | Male | 8 | Neuroblastoma + autologous bone marrow transplant | Proven |
| Central venous catheter; peripheral blood (culture) | Fever | Halo sign; cavity; bronchial wall thickening |
| 7 | Female | 1 | Hemangioendothe- lioma | Proven |
| Peripheral blood (culture); peritoneal cavity (ascitic fluid analysis) | Fever without neutropenia, shock and respiratory distress | Nodule; consolidation; cavity; ground- glass opacities; mosaic attenuation pattern; bronchial wall thickening |
| 8 | Female | 5 | Acute lymphoblastic leukemia refractory or relapsed | Proven |
| Peripheral blood (culture); urine (culture); lung (bronchoalveolar lavage) | Fever, shock and respiratory distress | Consolidation; pleural effusion; ground-glass opacities; bronchial wall thickening |
| 9 | Female | 11 | Acute lymphoblastic leukemia refractory or relapsed | Proven | Skin (biopsy) | Fever, respiratory distress and skin lesion | Consolidation; pleural effusion; ground-glass opacities | |
| 10 | Male | 3 | Retinoblastoma | Proven |
| Peripheral blood (culture) | Fever, shock and respiratory distress | Consolidation; ground-glass opacities; bronchial wall thickening |
| 11 | Female | 17 | Acute lymphoblastic leukemia | Probable | Lung (bronchoalveolar lavage) | Fever and shock | Halo sign; consolidation; cavity; ground glass opacities; bronchial wall thickening |
Chest CT findings by infectious etiology.
| CT finding | Proven/probable aspergillosis (n = 5) | Proven candidiasis (n = 5) | Proven fusariosis (n = 1) | Possible IFI (n = 29) |
|---|---|---|---|---|
| Halo sign, n (%) | 5 (100) | 1 (20) | 0 (0) | 21 (72) |
| Consolidation, n (%) | 2 (40) | 3 (60) | 1 (100) | 14 (48) |
| Cavity, n (%) | 2 (40) | 2 (40) | 0 (0) | 3 (10) |
| Nodules, n (%) | 0 (0) | 2 (40) | 0 (0) | 1 (3) |
| Ground-glass opacity, n (%) | 3 (60) | 3 (60) | 1 (100) | 22 (75) |
| Pleural effusion, n (%) | 1 (20) | 1 (20) | 1 (100) | 12 (41) |
1 finding (n = 4); 2 findings (n = 5); or ≥ 3 findings (n = 31).
Agreement between radiologists for chest CT findings.
| Chest CT finding | Interobserver agreement | |||
|---|---|---|---|---|
| First round | Second round[ | |||
| Kappa | Kappa | |||
| Halo sign | 0.609 | < 0.001 | 0.762 | < 0.001 |
| Consolidation | 0.609 | < 0.001 | 0.921 | < 0.001 |
| Cavity | 0.860 | < 0.001 | 0.860 | < 0.001 |
| Nodules | 0.649 | < 0.001 | 0.782 | < 0.001 |
| Ground-glass opacity | 0.813 | < 0.001 | 0.865 | < 0.001 |
| Pleural effusion | 0.900 | < 0.001 | 0.966 | < 0.001 |
Review of all CT scans.
Review of only the CT scans for which there were differences in interpretation in the first round.